3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term WinnersThe Motley Fool • 04/30/21
Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/30/21
Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR geneBusiness Wire • 04/28/21
Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic TherapiesBenzinga • 04/22/21
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene EditingBusiness Wire • 04/22/21
Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemiaMarket Watch • 04/21/21